Wednesday, December 14, 2022

Maxwell Biomedical Buys Cardialen

San Diego-based Maxwell Biomedical announced this morning that it has acquired Cardialen, a Minneapolis-based company that develops a low-energy defibrillation and cardioversion therapy designed to treat atrial fibrillation (AFib) and ventricular tachycardia (VT). Financial details of the transaction were not announced. Maxwell Biomedical was founded in 2019, and says it is working on an atrial pacing device that automatically detects AFib and imperceptibly delivers SRT to restore and maintain a normal heart rhythm.